Follow the Data: Discovering preclinical differences in bispecific impact on T cell & tumor cell interactions1

Research Area: Checkpoint & combination therapy

Development Stage: Discovery

Goal: Identify subtle differences and mechanism in therapies that engage T cells and the tumor microenvironment

[unex_ce_button id="content_10khx0ih9,column_content_611g46odk" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#29acd8" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#29acd8" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#9cc9d8" button_border_hover_color="#9cc9d8" button_link="https://www.isoplexis.com/request-a-seminar" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar
to follow our data >[/ce_button]

How our single-cell systems are making a difference

Solution: PSI revealed differences to enhance decision making

Finding: Enhanced bispecifics elicit more polyfunctional subsets than control when interacting with tumor target

Follow the data

PSI identified T cell potency upregulation triggered by novel bispecifics and revealed unique T cell cytokine mechanisms in response to tumor target. PSI was computed for CD4+ and CD8+ T cells; the profiles of both B2-OKT3 and hNKG2D-OKT3 showed significant polyfunctional upregulation relative to the Tz47-2C11 control sample, indicating their effectiveness in triggering a potent T cell response.

Both bispecific profiles are dominated by effector cytokines. hNKG2G-OKT3 stimulation is more potent in terms of polyfunctional strength index (PSI) than B2-OKT3, and sources of upregulation are revealed through the differential cytokine profile (i.e. chemoattractive and effector cytokines). CD4+ and CD8+ cells show the same trend and almost identical cytokine secretion with the exception of IL-5.1

[unex_ce_button id="content_om95el0ye,column_content_g32kkdowi" button_text_color="#424242" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px " button_bg_color="#c9c9c9" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#c9c9c9" button_border_radius="0px" button_text_hover_color="#424242" button_text_spacing_hover="1px" button_bg_hover_color="#e8e8e8" button_border_hover_color="#e8e8e8" button_link="https://isoplexis.com/wp-content/uploads/2019/02/IsoPlexis-AppHighlight-Bispecifics.pdf" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application highlight
to learn more >[/ce_button]

IsoPlexis finds critical differences

PAT PCA visualization illustrates the differential T cell upregulation triggered by novel hNKG2D-OKT3 and B2-OKT3 bispecifics, by identifying highly functional cell subsets. CD4+ T cells from the hNKG2D-OKT3 group (orange) secreted polyfunctional effector proteins more frequently than those cultured in the presence tumor cells and the B2-OKT3 bispecific (blue).

This hNKG2D-OKT3 polyfunctionality includes diverse combinations of secretions, whereas B2-OKT3 overall elicited fewer polyfunctional and more monofunctional secretions. The increased polyfunctional response and T cell potency driven by hNKG2D-OKT3 indicates its potential superiority over B2-OKT3.1